The clinical effect of naproxen sodium after arthroscopy of the knee: A randomized, double-blind, prospective study

Rasmussen, Sten; Thomsen, Søren; Madsen, Sabine; Rasmussen, Per Joen Svabo; Simonsen, Ole

doi:10.1016/s0749-8063(05)80309-3

Cited by 27 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared with a placebo, naproxen was more likely to relieve pain following arthroscopic knee procedures [43–45] and total knee or hip arthroplasty [46]. Naproxen use also reduced pain intensity [43,45] and rescue analgesia consumption [43,44] following therapeutic arthroscopic procedures. One study demonstrated a reduction in the pain intensity difference, but not in pain intensity or rescue analgesia consumption, in the intervention group [46].…”

Section: Resultsmentioning

confidence: 99%

Reducing the Pain: A Systematic Review of Postdischarge Analgesia Following Elective Orthopedic Surgery

2012

View full text Add to dashboard Cite

Opioids and cyclooxygenase-2 inhibitors are effective in providing analgesia in the extended postoperative period following orthopedic surgery with a minimal side-effect profile, while nonselective NSAIDs need to be treated with caution. Homeopathy is not an effective analgesic, while acupuncture has varied evidence and effectiveness. Treatment of postoperative fatigue may also improve analgesia control. This study provides orthopedic surgeons with a basis for evidence-based prescribing of postdischarge analgesia. However, further studies to validate these results against modern reporting standards are needed.

show abstract

Section: Resultsmentioning

confidence: 99%

Reducing the Pain: A Systematic Review of Postdischarge Analgesia Following Elective Orthopedic Surgery

2012

View full text Add to dashboard Cite

show abstract

“…In a double-blind, randomized, prospective study of human patients undergoing arthroscopic surgery, those who were administered a prostaglandin inhibitor (naproxen sodium) had significantly less pain, less synovitis, less effusion, and faster recovery (Ogilvie-Harris et al, 1985;Rasmussen et al, 1993) than those without. In equally as large a prospective study, no advantages were observed over control group of patients when compared to physical therapy and administration of the NSAID, diclofenac (Birch et al, 1993).…”

Section: Postoperative Painmentioning

confidence: 86%

“…In a double‐blind, randomized, prospective study of human patients undergoing arthroscopic surgery, those who were administered a prostaglandin inhibitor (naproxen sodium) had significantly less pain, less synovitis, less effusion, and faster recovery (Ogilvie‐Harris et al. , 1985; Rasmussen et al. , 1993) than those without.…”

Section: Postoperative Painmentioning

confidence: 99%

The use of phenylbutazone in the horse

Soma

Uboh

Maylin

2011

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

This review presents a brief historical prospective of the genesis of regulated medication in the US racing industry of which the nonsteroidal anti-inflammatory drug (NSAID) phenylbutazone (PBZ) is the focus. It presents some historical guideposts in the development of the current rules on the use of PBZ by racing jurisdictions in the US. Based on its prevalent use, PBZ remains a focus of attention. The review examines the information presented in a number of different models used to determine the effects and duration of PBZ in the horse. They include naturally occurring lameness and reversible-induced lameness models that directly examine the effects and duration of the administration of various doses of PBZ. The review also examines indirect plasma and tissue models studying the suppression of the release of arachidonic acid-derived mediators of inflammation. The majority of studies suggest an effect of PBZ at 24 h at 4.4 mg/kg. This reflects and substantiates the opinion of many clinical veterinarians, many of whom will not perform a prepurchase lameness examination unless the horse is free of NSAID. This remains the opinion of many regulatory veterinarians responsible for the prerace examination of race horses that they wish to examine a horse without the possibility of an NSAID interfering with the examination and masking possible musculoskeletal conditions. Based on scientific studies, residual effects of PBZ remain at 24 h. The impact of sustained effect on the health and welfare of the horse and its contribution to injuries during competition remains problematic.

show abstract

“…Naproxen is clinically effective in patients with postoperative pain [3]. The postoperative pain period is often dominated by the need to find effective ways of blocking the inflammatory reaction and relieving pain [4].…”

Section: Introductionmentioning

confidence: 99%

Single-dose oral naproxen for acute postoperative pain: a quantitative systematic review

et al. 2003

View full text Add to dashboard Cite

BackgroundNaproxen and naproxen sodium are non-steroidal anti-inflammatory drugs used in a variety of painful conditions, including the treatment of postoperative pain. This review aims to assess the efficacy, safety and duration of action of a single oral dose of naproxen/naproxen sodium for moderate to severe acute postoperative pain in adults, compared with placebo.MethodsThe Cochrane Library (issue 4 2002), EMBASE, PubMed, MEDLINE and an in-house database were searched for randomised, double blind, placebo controlled trials of a single dose of orally administered naproxen or naproxen sodium in adults with acute postoperative pain. Pain relief or pain intensity data were extracted and converted into dichotomous information to give the number of patients with at least 50% pain relief over 4 to 6 hours. Relative benefit and number-needed-to-treat were then calculated. The percentage of patients with any adverse event, number-needed-to-harm, and time to remedication were also calculated.ResultsTen trials with 996 patients in met the inclusion criteria. Six trials compared naproxen sodium 550 mg (252 patients) with placebo (248 patients); the NNT for at least 50% pain relief over six hours was 2.6 (95% confidence interval 2.2 to 3.2). There was no significant difference between the number of patients experiencing any adverse event on treatment compared with placebo. Weighted mean time to remedication was 7.6 hours for naproxen sodium 550 mg (206 patients) and 2.6 hours for placebo (205 patients). Four other trials used lower doses.ConclusionA single oral dose of naproxen sodium 550 mg is an effective analgesic in the treatment of acute postoperative pain. A low incidence of adverse events was found, although these were not reported consistently.

show abstract

The clinical effect of naproxen sodium after arthroscopy of the knee: A randomized, double-blind, prospective study

Cited by 27 publications

References 21 publications

Reducing the Pain: A Systematic Review of Postdischarge Analgesia Following Elective Orthopedic Surgery

Reducing the Pain: A Systematic Review of Postdischarge Analgesia Following Elective Orthopedic Surgery

The use of phenylbutazone in the horse

Single-dose oral naproxen for acute postoperative pain: a quantitative systematic review

Contact Info

Product

Resources

About